Has Mitchell Haut, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,780 in general payments to Mitchell Haut, MD across 227 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mitchell Haut, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mitchell Haut, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mitchell Haut, MD

Hematology & Oncology · Canton, OHNPI 1023015674

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,279 and has fallen 98.9% since, to $25 in 2022.

$3,780in general payments, 2019–2025

Across 227 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$415
Bristol Myers Squibb$231
Novartis$211
Genentech USA, Inc.$201
Eisai Inc.$194
AstraZeneca$193
plus $2K from 39 others

$308,331in research payments, 2019–2025

Across 136 payments — averaging $2267.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$137K
Regeneron$41K
Sanofi US Services Inc.$30K
Bristol Myers Squibb$23K
Astrazeneca UK Limited$21K
Daiichi Sankyo Inc.$19K
plus $38K from 5 others

What the payments were for

Food & beverage$3,59995%
Education$1815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	31	$415
Bristol Myers Squibb	13	$231
Novartis	13	$211
Genentech USA, Inc.	15	$201
Eisai Inc.	10	$194
AstraZeneca	11	$193
Amgen	10	$164
Merck	10	$158
Sanofi	8	$145
Johnson & Johnson(2 entities)	8	$139
Clovis Oncology, Inc.	4	$132
GSK	5	$113
AMAG Pharmaceuticals, Inc.	6	$110
Lilly USA, LLC	7	$108
Puma Biotechnology, Inc.	8	$99
Bayer	5	$91
Boehringer Ingelheim	4	$68
Seagen Inc.	5	$68
Regeneron Healthcare Solutions, Inc.	2	$65
Incyte Corporation	4	$64
Beigene USA, Inc.	4	$62
Pfizer	4	$60
Partner Therapeutics, Inc.	3	$59
Astellas Pharma US Inc	3	$59
Tesaro, Inc.	3	$48
Lexicon Pharmaceuticals, Inc.	2	$48
EMD Serono, Inc.	3	$46
Dendreon Pharmaceuticals LLC	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	3	$43
Ipsen Biopharmaceuticals, Inc	2	$40
Exelixis Inc.	2	$39
Agios Pharmaceuticals, Inc.	2	$36
Pharmacyclics LLC, An Abbvie Company	2	$35
Gilead(2 entities)	2	$25
Foundation Medicine, Inc.	1	$22
Secura Bio, Inc.	1	$21
Helsinn Therapeutics (U.S.), Inc.	1	$18
Advanced Accelerator Applications	1	$17
Array Biopharma Inc	1	$15
Acceleron Pharma, Inc.	1	$14
AVEO Pharmaceuticals, Inc.	1	$14
Rigel Pharmaceuticals, Inc.	1	$12
Shionogi Inc	1	$12
Jazz Pharmaceuticals Inc.	1	$12
Heron Therapeutics, Inc.	1	$10

How this compares

$3,780 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Medicare billing

Part B allowed, 2024

$57,114

Medicare patients

174

Services billed

590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Abiraterone Acetate	19	$7,445
Letrozole	74	$1,329
Prochlorperazine Maleate	41	$544
Prednisone	21	$216
Anastrozole	13	$197
Acyclovir	15	$182
Dexamethasone	16	$181
Triamcinolone Acetonide	12	$171
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	14	$127

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Canton

Shruti TrehanCanton$57K
Hillard LazarusCleveland$2M
Kasra KaramlouSandusky$1.8M
David WaterhouseCincinnati$1.3M
Taral PatelColumbus$888K
Tarek ChidiacColumbus$765K
Saulius GirniusMontgomery$707K
Ronald BukowskiCleveland$594K
Balazs HalmosCleveland$568K
Jorge GarciaCleveland$513K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →